

**BLAU FARMACÊUTICA S.A.**

Publicly Held Company  
NIRE 35.300.416.406  
CVM Code No. 2462-7

**NOTICE TO SHAREHOLDERS****Payment of fractions of shares resulting from the bonus share**

BLAU FARMACÊUTICA S.A. (Ticker: **BLAU3**; "Blau" or "Company"), hereby informs its shareholders and the market in general, in addition to the notice to shareholders disclosed on March 6, 2026, that the fractions of shares resulting from the bonus in shares were grouped in whole numbers and sold at B3 S.A. – Brasil, Bolsa, Balcão ("B3"), in an auction held on 03/10/2026.

In this auction, 4,586.1 shares were sold in the amount of R\$ 10.59078519875 per share. The value of the fractions will be made available to shareholders who are entitled to receive it on 04/08/2026.

The distribution of the amounts will occur as follows:

- a) Shareholders with complete registration data: the amounts will be deposited in the checking account indicated in the respective shareholders' registration.
- b) shareholders with shares deposited in the B3 Central Depository: the amounts will be credited directly to the Central Depository, which will be responsible for transferring them to the respective shareholder through its custody agent; and
- c) other shareholders not identified or without complete registration data: the amounts will be available to the Company, for the legal period, for receipt by the respective holder upon provision of complete registration data.

The funds attributed to investors, resident and non-resident in Brazil, may be subject to income tax on any capital gains, which will be taxed as "net gains", under the terms of the legislation in force. Thus, the appropriate tax treatment must be identified directly by the respective shareholders, with the assistance of their advisors.

Cotia, March 31, 2026

**Douglas Leandro Rodrigues**  
Chief Financial and Investor Relations Officer

**About Blau Farmacêutica:**

Blau is a leading multinational pharmaceutical company in the hospital segment and a pioneer in biotechnology in Brazil, with a portfolio of proprietary brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, and several other therapeutic classes. Blau has an international presence, operating in Brazil and seven other Latin American countries (Argentina, Colombia, Chile, Ecuador, Mexico, Peru, and Uruguay), in addition to a plasma collection operation in the United States. It has a modern pharmaceutical industrial complex in Brazil, consisting of five industrial plants with state-of-the-art technology, dedicated to serving the local market and exports.